Investment Rating - The report maintains a "Strong Buy" rating for 加科思-B (01167.HK) [2] Core Views - 加科思 has released its 2025 annual performance report, showcasing the efficacy data of its pan-KRAS inhibitor JAB-23E73, which demonstrates potential as a best-in-class treatment [2] - The company is expected to achieve significant revenue growth in the coming years, with projected revenues of 670 million in 2026, 493 million in 2027, and 455 million in 2028, reflecting a substantial recovery from a revenue of 54 million in 2025 [4] - The net profit is projected to turn positive in 2026, with estimates of 417 million, 234 million, and 167 million for the years 2026, 2027, and 2028 respectively [4] - The target price for the stock is set at 11.65 HKD, compared to the current price of 6.99 HKD, indicating a significant upside potential [4] Financial Summary - Total revenue for 2025 is reported at 54 million, with a year-on-year decline of 65.6%, followed by an expected increase of 1,152.2% in 2026 [4] - The company anticipates a net profit of -146 million in 2025, transitioning to a profit of 417 million in 2026, marking a growth of 385.5% [4] - Earnings per share (EPS) is projected to improve from -0.18 in 2025 to 0.53 in 2026 [4] - The price-to-earnings (P/E) ratio is expected to shift from -33 in 2025 to 12 in 2026, indicating a positive market sentiment [4] Clinical Development Insights - The pan-KRAS inhibitor JAB-23E73 has shown promising efficacy data, with an overall response rate (ORR) of 38.5% in a domestic pancreatic cancer subgroup [8] - The company is advancing its clinical trials, with plans to initiate a Phase II trial for JAB-23E73 in China in the first half of 2026 [8] - The next-generation ADC platform is expected to expand into multiple targets and indications, with significant innovations underway [8]

Investment Rating - The report assigns a "Strong Buy" rating to the company for the first time [5][8]. Core Insights - The company has successfully commercialized its first product, the KRAS G12C inhibitor, and has established a partnership with AstraZeneca for its next-generation pan-KRAS inhibitor, JAB-23E73, which is expected to accelerate global value realization [5][6]. - The company is innovating in the ADC field with tADC and iADC platforms, which aim to overcome traditional treatment limitations and enhance therapeutic efficacy [5][6]. - The financial projections indicate significant revenue growth, with expected revenues of 234 million, 627 million, and 508 million CNY for 2025, 2026, and 2027, respectively, alongside a notable increase in net profit in 2026 [5][8]. Financial Summary - Total revenue (CNY million): 156 in 2024A, 234 in 2025E, 627 in 2026E, and 508 in 2027E, with year-on-year growth rates of 145.1%, 50.5%, 167.6%, and -19.1% respectively [5]. - Net profit attributable to shareholders (CNY million): -156 in 2024A, -15 in 2025E, 313 in 2026E, and 192 in 2027E, with year-on-year growth rates of 56.6%, 90.7%, 2,258.6%, and -38.6% respectively [5]. - Earnings per share (CNY): -0.20 in 2024A, -0.02 in 2025E, 0.40 in 2026E, and 0.24 in 2027E [5]. Market Position and Product Pipeline - The company has a comprehensive pipeline focusing on KRAS and other challenging drug targets, with its first commercial product already contributing to cash flow [6][33]. - The partnership with AstraZeneca for JAB-23E73 is expected to enhance the company's competitive edge in the oncology sector [7][33]. - The company is advancing multiple ADC candidates, including tADC and iADC, which are anticipated to address unmet medical needs in cancer treatment [5][6].

Investment Rating - The report assigns a "Strong Buy" rating to the company for the first time [5][8]. Core Insights - The company has significant potential for value re-evaluation, particularly with its pan-KRAS inhibitors and strategic collaborations, notably with AstraZeneca [5][6]. - The first commercial product, KRAS G12C inhibitor Goleirese, has been approved and is expanding its indications, contributing to cash flow [5][33]. - The next-generation ADC platforms, tADC and iADC, are expected to overcome traditional treatment limitations and enhance the company's competitive edge in oncology [5][6][7]. Financial Summary - Projected total revenue (in million CNY) for 2024A, 2025E, 2026E, and 2027E is 156, 234, 627, and 508 respectively, with year-on-year growth rates of 145.1%, 50.5%, 167.6%, and -19.1% [5][8]. - Expected net profit attributable to shareholders (in million CNY) for the same years is -156, -15, 313, and 192, with growth rates of 56.6%, 90.7%, 2,258.6%, and -38.6% [5][8]. - The estimated price-to-earnings ratio (P/E) for 2026 is 14, and for 2027 is 23, indicating a potential for profitability [5][8]. Product Pipeline and Collaborations - The company has developed a differentiated innovation drug research system targeting difficult drug targets like KRAS, with a focus on pan-KRAS inhibitors [6][33]. - The collaboration with AstraZeneca for the pan-KRAS inhibitor JAB-23E73 is expected to accelerate the global value realization of the company's pipeline [5][6][7]. - The company is advancing its ADC platforms, with tADC utilizing KRAS inhibitors as payloads and iADC using STING agonists, aiming to address challenges in traditional therapies [5][6][7]. Market Position and Competitive Landscape - The company is positioned to leverage its innovative drug development capabilities in the oncology sector, particularly with its KRAS-targeted therapies [5][6][7]. - The competitive landscape for pan-KRAS inhibitors is evolving, with the company’s JAB-23E73 showing promising clinical data and safety profiles compared to competitors [5][6][7].

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [2] Core Views - The pharmaceutical and biotechnology industry index increased by 3.08%, ranking third among 31 primary industries, outperforming the CSI 300 index which rose by 0.94% [5][17] - The report highlights the acceleration of internationalization of innovative drugs, with a focus on two main directions: the global multi-center clinical capabilities and differentiated technology platforms, as well as short-term opportunities driven by ASCO data [8][9] Industry Performance - The valuation of the pharmaceutical and biotechnology industry as of May 23, 2025, is a PE (TTM overall method, excluding negative values) of 27.60x, up from 26.77x in the previous period, indicating an upward trend but still below the average [22] - The top three sub-industries in terms of PE are vaccines (52.08x), hospitals (37.38x), and medical devices (33.40x), while the lowest valuation is in pharmaceutical circulation (15.18x) [22] Important Industry News - The CDE released guidelines for clinical trials of Alzheimer's disease drugs to provide technical standards for scientific research and evaluation [27] - AbbVie’s c-Met ADC "Teliso-V" received FDA approval, marking it as the first of its kind globally [28] - The report mentions significant collaborations, such as Pfizer's partnership with 3SBio for a PD-1/VEGF bispecific antibody, valued at over $6 billion [8][51] Company Dynamics - Hengrui Medicine officially listed on the Hong Kong Stock Exchange with an IPO price of HKD 44.05 per share, achieving a market capitalization of over HKD 290 billion [44][45] - The report notes that 35 listed companies in the pharmaceutical and biotechnology sector experienced a net reduction in shareholder holdings amounting to CNY 1.336 billion during the reporting period [5]